GLP-1 Telehealth for Medicare Patients With No Coverage: Your 2026 Options

By the Weight Loss Provider Guide Editorial Team · Last verified May 28, 2026. Next review: August 2026.

Disclosure: We may earn a commission when you start with some of the providers we link to. It costs you nothing extra, and it never changes which option we tell you is cheapest or best. In fact, the lowest-cost option on this page isn’t one we earn from — and we say so.

If you’re looking for GLP-1 telehealth for Medicare patients with no coverage, here’s the short version: you have three real ways to get Ozempic, Wegovy, Zepbound, or the new weight-loss pill — and two of them are so new that most people (and most websites) haven’t caught up yet.

Here’s the bottom line, before you scroll another inch.

Regular Medicare drug coverage won’t pay for a GLP-1 prescribed only for weight loss. That part is true, and it’s not your plan being difficult — it’s a federal law. But it is not the end of the road:

• 1Path 1 — A covered health reason. Medicare can cover a GLP-1 when it’s prescribed for type 2 diabetes, heart-disease risk, or sleep apnea. Check this first. It’s the cheapest.
• 2Path 2 — The new $50-a-month Medicare GLP-1 Bridge. From July 1, 2026 through December 31, 2027, people who qualify can get Wegovy, Zepbound (KwikPen), or Foundayo for a $50 copay. ^[1]
• 3Path 3 — Cash-pay, right now. Real, FDA-approved, brand-name medication is available without billing insurance for $149–$449 a month. Cash-pay telehealth can handle the whole thing — and yes, Medicare patients can use it.

We’re Weight Loss Provider Guide, an independent comparison resource for GLP-1 telehealth providers. We read the CMS rules, both drug makers’ direct-pay prices, and every major telehealth service so you don’t have to open a dozen tabs to make one decision. The hard truth most “cheap online GLP-1” pages won’t tell you: paying cash should be your fallback, not your first move. Check the two cheaper paths first. We’ll show you how, in plain English, in about five minutes.

Find your path in 30 seconds

Most people land here in one of five situations. Find the row that sounds like you, then jump to that section.

Does GLP-1 telehealth for Medicare patients with no coverage actually work?

Quick answer: Yes — but on a cash basis, not by billing Medicare. A telehealth visit and your drug coverage are two separate things. Most telehealth weight-loss services don’t bill insurance at all, so you simply pay them directly, which sidesteps Medicare’s weight-loss rule. The one trap: Medicaid often blocks you from these programs entirely, even to pay cash — and Medicaid is not the same as Medicare.

Let’s clear up the biggest mix-up first, because it trips up almost everyone.

A telehealth visit is not the same as drug coverage. A telehealth doctor can talk to you and write a prescription. That’s the visit. Whether Medicare pays for the medicine is a totally separate question — and the answer depends on the rules below, not on how you saw the doctor.

It also helps to know that “no coverage” usually means one of three things:

1. No weight-loss coverage at all — your plan flat-out excludes drugs used for weight loss.
2. A denied prior authorization — your plan asked your doctor to get the drug approved before it would pay (“prior authorization”), and said no.
3. No coverage for that specific drug — your plan covers some GLP-1s but not the one you were prescribed.

Each one points you toward a different fix. The rest of this page walks through them in the order that saves you the most money.

Why Medicare says “no” — and the one thing that changes the answer

Quick answer: A federal law bars Medicare Part D — the part of Medicare that covers prescriptions — from paying for any drug used for weight loss. So a GLP-1 prescribed only to lose weight isn’t covered under regular Part D. But the same drug can be covered when it’s prescribed for a different approved reason, and a brand-new program now covers it for obesity at $50 a month starting July 1, 2026. ^[1][2]

If a pharmacist or doctor told you Medicare won’t pay for your Ozempic, Wegovy, or Zepbound, they were almost certainly right.

Here’s why. Federal law leaves “agents when used for weight loss” out of Medicare’s drug benefit, and CMS kept that exclusion in place in 2026. ^[2] It’s a legal wall built into the program, not a choice your plan is making — plans aren’t allowed to cover a weight-loss-only prescription, even if they wanted to.

This is the part that surprises people: the reason on your prescription decides coverage — not the drug. The exact same medicine can be covered or denied depending on why it was prescribed. Tirzepatide written as Mounjaro for diabetes is coverable. The identical molecule written as Zepbound for weight loss is not. ^[3]

This nearly changed. In late 2024, the prior administration proposed letting Medicare cover obesity drugs, which would have reached about 3.4 million people. But in April 2025 the current administration decided not to finalize that change and kept the weight-loss exclusion in place. ^[4] So that’s the wall. Now here are the three legitimate ways around it — starting with the cheapest.

The 3 paths, ranked cheapest first

Quick answer: Check Medicare paths before cash-pay paths. The order that saves you the most money is: (1) a covered medical reason, (2) the $50 Bridge program if you qualify, then (3) cash-pay for FDA-approved brand-name medication, which runs $149–$449 a month with no insurance.

Below is the whole decision on one screen. We built this table because nobody else puts all of it in one place — what Medicare pays, what it costs you, and who each path is for. This is the map. The sections after it are the directions.

Read it top to bottom. The further up you can qualify, the less you pay. Let’s take them one at a time.

Quick answer: Medicare Part D can cover a GLP-1 when it’s prescribed for a qualifying approved condition instead of for weight loss: type 2 diabetes, reducing cardiovascular risk, or obstructive sleep apnea. If you have one of these, you may already have a covered path and not know it. Covered-drug spending is capped at $2,100 out of pocket in 2026. ^[3][5]

This is the most overlooked option, and for the people it fits, it beats everything else on this page.

The rule is simple: if a GLP-1 has an FDA-approved use beyond weight loss, your Part D plan may cover it for that use ^[3] — though normal plan rules still apply, like prior authorization, “step therapy” (trying a cheaper drug first), and quantity limits. Here’s how it breaks down by medicine:

One more reason this path wins on cost: when a GLP-1 is covered under Part D, your yearly out-of-pocket spending is capped. In 2026, Part D caps your out-of-pocket cost for covered drugs at $2,100, with a deductible no higher than $615. ^[5] After you hit the cap, covered drugs cost you $0 for the rest of the year. That’s a very different picture from paying cash every month — which is exactly why it’s worth ruling this path in or out before anything else.

Quick answer: The Medicare GLP-1 Bridge is a temporary federal program that, from July 1, 2026 through December 31, 2027, covers Foundayo, Wegovy, and the Zepbound KwikPen for obesity at a $50 monthly copay for eligible Part D members. You qualify with a BMI of 35+, or 27+ with another health condition, plus a prior-authorization request from your prescriber. ^[1]

This is the development that changes the answer for millions of people — and it’s so new that a lot of articles still get it wrong. (We found pages claiming Medicare “already covers” these drugs, or that a law passed. Neither is true.) Here’s what the program actually is, straight from CMS.

What it is

The Bridge is a short-term demonstration run by CMS that gives eligible Medicare Part D members access to certain GLP-1 drugs at a $50 copay between July 1, 2026 and December 31, 2027. ^[1] It runs outside your normal Part D drug benefit, so your plan doesn’t have to opt in for you to use it.

Covered medicines under the Bridge: Foundayo (all forms), Wegovy (the injection and the new oral pill), and Zepbound — the KwikPen only. Zepbound single-dose vials and single-dose pens are not covered through the Bridge. ^[1] Ozempic and Mounjaro aren’t in the Bridge either — they’re approved for diabetes, not weight loss — but they can be covered under regular Part D if you have diabetes (see Path 1). ^[1]

Who qualifies

Your prescriber must submit a prior-authorization request stating you meet one of these, measured at the time you started GLP-1 treatment: ^[1]

• •BMI of 35 or higher, or
• •BMI of 30 or higher plus one of: heart failure with preserved ejection fraction, uncontrolled high blood pressure (above 140/90 despite two blood-pressure medicines), or chronic kidney disease (stage 3a or higher), or
• •BMI of 27 or higher plus one of: prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.

The prescription must also come with “lifestyle modification” — basic nutrition and activity guidance, as the drug’s label calls for. ^[1] One helpful detail: eligibility is based on your BMI when you first started the medicine, not your BMI on the day the paperwork is filed. CMS gives the example of someone who started at a BMI of 37 and later dropped to 34 — they still qualify based on the 37. ^[1]

How it actually works (and a telehealth detail that matters)

The Bridge runs through a single national processor — Humana — instead of your Part D plan. Your prescriber and pharmacy send the prior authorization and the claim to Humana, not to your plan. ^[1] You still need to have a Part D plan (a standalone drug plan, or a Medicare Advantage plan that includes drug coverage), but the medicine itself flows through the Bridge. It works even if the drug isn’t on your plan’s covered-drug list. ^[1]

Here’s the part that matters if you’re using telehealth: your prescriber does not have to be enrolled in Medicare to write a Bridge prescription or file the paperwork. They only have to not be on Medicare’s Preclusion List. ^[1] So a qualified telehealth clinician can set this up for you.

The three catches nobody mentions

One more rule worth knowing: if your GLP-1 actually qualifies under regular Part D — say, Zepbound for sleep apnea or Wegovy for heart-disease risk — it goes through your plan, not the Bridge. ^[1] So check Path 1 first.

Bottom line on the Bridge: if your BMI is 35+ (or 27+ with another health issue) and you’re on a drug plan, this is very likely your best-value path once it opens July 1, 2026 — far cheaper than cash. The smart move now is to talk to your doctor so the prior authorization is ready to go the day it launches. And if you start on the Bridge, ask your prescriber what the backup plan is before December 31, 2027.

Quick answer: You don’t need any insurance to get an FDA-approved GLP-1 anymore. Through the drug makers’ own pharmacies, Zepbound runs $299–$449/month, Wegovy about $349/month, and the newest pills, Foundayo and oral Wegovy, start at $149/month. Cash-pay telehealth can prescribe the same brand-name medicines and handle everything in one place. And yes — Medicare patients can use these cash programs. You just can’t bill them to Medicare.

This is the path most people on this page actually need, and 2026 has been the year cash prices dropped hard. Two things did it: the drug makers launched direct-to-you pharmacies, and a federal pricing deal pushed prices lower still. ^[12]

The Medicare GLP-1 No-Coverage Cost Map

Cash prices verified late May 2026. “FDA-approved” means real, brand-name medicine made by the manufacturer.

The cheapest FDA-approved options are now pills. Foundayo (orforglipron) launched in April 2026 and self-pays from $149/month through LillyDirect, and it doesn’t have to be taken on an empty stomach or at a set time. ^[17] Oral Wegovy also starts around $149/month. ^[15] If you dislike needles, that’s a real advantage.

The drug makers set the price floor. LillyDirect and NovoCare sell direct, so you’re getting the real medicine at the lowest cash price.

Medicare patients are welcome to pay cash through most of these — with one big exception we explain in the next section.

Can a telehealth company actually help a Medicare patient? (Yes — here’s the exact rule)

Quick answer: Yes, on a cash basis. Most telehealth weight-loss services don’t bill insurance at all, so as a Medicare patient you pay out of pocket like any cash customer — and Medicare’s coverage rules don’t get in the way. The trap to avoid: Medicaid (and some other government plans) often makes you ineligible for these programs entirely, even to pay cash. Medicare and Medicaid are not the same thing here.

This is the question the search is really asking, and it’s where almost every other page gets vague. So let’s be precise, using Ro — the clearest example and our top pick for this situation.

Ro will not coordinate coverage with Medicare, Supplemental Medicare, or Tricare. But Medicare patients can join the Ro Body program and pay cash for FDA-approved medicines. ^[14] In plain terms: Ro won’t help you bill Medicare, but as a Medicare patient you can absolutely use Ro as a cash customer and get a real, brand-name GLP-1.

Why does paying cash sidestep the whole Medicare problem? Because the obstacle was never the telehealth visit — it was Part D’s weight-loss rule. When you pay cash, there’s no Part D claim to deny. You’re simply a self-pay patient, the same as someone with no insurance at all.

FDA-approved brand-name vs compounded: what we recommend, and why

Quick answer: For Medicare patients, we recommend an FDA-approved, brand-name GLP-1 over a compounded version. Brand-name medicine is now available for cash at $149–$449/month, it’s the exact product these drugs were studied as, and the FDA is moving to shut down large-scale compounding of semaglutide and tirzepatide. Compounded GLP-1s are not FDA-approved products.

You’ll see telehealth ads offering “semaglutide” for $99. Some of those are compounded — meaning mixed by a pharmacy rather than made by the original manufacturer. We’re not here to scare you off compounded medicine in every case. But for a Medicare-age patient weighing options today, the math has shifted, and so has the law.

Compounded versions aren’t FDA-approved. ^[18] The drug shortages that once let pharmacies make these in bulk ended in 2024 and 2025, and on April 30, 2026 the FDA proposed closing the last pathway for large-scale compounding of semaglutide, tirzepatide, and liraglutide. ^[9] That proposal is expected to be finalized later in 2026. The practical result: cheap, widely available compounded GLP-1s have been drying up. Meanwhile, FDA-approved brand-name medicine is now in the same price range compounded used to be. So the case for choosing brand-name is stronger than it’s ever been.

That’s why, when this page recommends a telehealth provider, it recommends ones that prescribe FDA-approved brand-name medicine.

Our top telehealth pick for Medicare cash-pay: Ro

Best for: a Medicare patient who wants real, brand-name medicine plus a doctor and ongoing support, handled in one place — paying cash.

Ro is an all-in-one telehealth company. It handles the visit, the prescription, the pharmacy, and your check-ins, and it pairs you with a care team you can reach. ^[14] For a Medicare patient who doesn’t have a weight-management doctor and wants the whole thing guided, that bundle is the draw. And its medicine prices match the direct-from-maker programs — so you’re not paying a markup on the drug. You’re paying the membership for the care around it.

We may earn a commission, at no cost to you. The direct-from-maker option above is cheaper, and we said so.

A strong second option: Sesame

Best for: a Medicare patient who’d rather compare providers and prices in a marketplace, wants one of the broadest brand-name menus, or wants Costco-member pricing on Wegovy or Ozempic.

Where Ro bundles everything into one membership, Sesame (Success by Sesame) is a marketplace: you pay a flat subscription — $99/month, or as low as $59/month on the annual plan — and the medicine is billed separately. ^[15] You pick your own provider, and the menu is wide, including Wegovy, Zepbound, Ozempic, Mounjaro, and Foundayo. Sesame doesn’t bill insurance for the visit or the subscription, so a Medicare patient can use it on a cash basis. (One note: Novo Nordisk’s introductory medication promo on Sesame excludes people in government drug plans, so as a Medicare patient you’d pay the regular cash medication price, not the intro price. ^[15]) Confirm the details for your situation before you book.

Which one fits you? If you live outside a major metro and want to be sure a provider can treat you, check GLP-1 providers available in all 50 states before you sign up.

Who should NOT start a GLP-1 without a clinician’s review

Quick answer: Do not start a GLP-1 — through telehealth or anywhere else — without a real clinician reviewing your history if you have a personal or family history of medullary thyroid cancer or the genetic condition MEN 2, a prior serious reaction to a GLP-1, or a history of pancreatitis. These medicines also are not for use in pregnancy.

What you’ll actually pay each month

Quick answer: If you qualify for a covered path, expect your plan’s cost-sharing, capped at $2,100/year in 2026. If you qualify for the Bridge, $50/month from July 1, 2026. If you’re paying cash, plan on $149–$449/month depending on the medicine — pills are cheapest, brand-name injections sit in the middle, and a guided telehealth membership adds a fee on top.

What to ask your doctor or telehealth provider

Quick answer: Ask which payment path they’re using — Bridge, regular Part D, or cash. Then ask about the drug, dose, pharmacy, prior-authorization status, ongoing monthly cost, and follow-up plan. This one conversation prevents the most expensive mistake: thinking you’re using Medicare when you’re actually paying cash.

Copy these. They work in person or in a telehealth message.

What gets Medicare patients denied, delayed, or overcharged

Quick answer: The five most common problems are: asking Part D to cover weight loss directly, missing the Bridge’s BMI/diagnosis paperwork, assuming a manufacturer coupon works on Medicare, comparing a low intro price to an ongoing price, and picking a provider that blurs compounded with FDA-approved medicine.

Run through this quick checklist before you hand over a card:

If you’ve already been denied and think it was a mistake, our guide to getting prior authorization handled for you walks through appeals and paperwork.

Quick answer: Not every plan behaves the same way. A Medicare Advantage plan with drug coverage follows the same weight-loss rule but counts for the Bridge. Medigap isn’t drug coverage. Medicaid can block you from cash-pay telehealth. And aging into Medicare often means losing coverage you had — so plan ahead.

What real Medicare shoppers are running into

You’re not the only one frustrated by this. In Medicare and weight-loss forums, the same lines come up again and again: “My plan won’t cover it unless I’m diabetic.” “A prior authorization is pointless — weight-loss drugs just aren’t covered on my plan.” “I’m paying out of pocket because I don’t have diabetes or sleep apnea.” That’s the real wall people hit — and it’s exactly why this page leads with the covered paths first, then shows you a safe, FDA-approved cash route if those don’t fit.

It’s also fair to be cautious about buying medicine online at any age. Two things should reassure you about the brand-name, cash-pay route specifically. First, the medicine is the real, manufacturer-made product — through LillyDirect, NovoCare, or a brand-name-only telehealth service, you’re getting the same Wegovy, Zepbound, or Foundayo a pharmacy dispenses, just priced and shipped directly. Second, these tools are mainstream now: Ro’s free coverage-checking tool alone has helped hundreds of thousands of people understand their options. ^[21] Independent reviewers also point to Ro’s brand-name-only menu and insurance navigation as real strengths. ^[14]

How we verified this — and what we checked

This page exists because a Medicare patient shouldn’t have to open a dozen tabs across CMS, two drug-maker pharmacies, and a stack of provider pages just to learn what they can do today. We did that work and put it in one place.

We’re Weight Loss Provider Guide, an independent comparison resource for GLP-1 telehealth providers. We earn affiliate commissions on some providers, which we disclose — and that money does not change which option we tell you is cheapest or best. (The cheapest option on this page, buying direct from the maker, is one we don’t earn from.)

Prices and program rules are changing monthly right now. We re-verify cash prices and Bridge status monthly and update the date at the top. Last verified: May 28, 2026. Spot-check any figure against the linked source before you act on it.

What to do today if Medicare says no

Here’s the whole page in one decision:

Frequently asked questions

Sources

1. Centers for Medicare & Medicaid Services (CMS) — Medicare GLP-1 Bridge (program dates, $50 copay, eligibility criteria, covered drugs/formulations including Zepbound KwikPen only, Humana central processor, Preclusion List rule, out-of-pocket/LIS/coupon caveats). cms.gov
2. KFF — What Medicare’s Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries (statutory weight-loss exclusion; Bridge operates outside Part D). kff.org
3. Wellcare — Does Medicare Cover Weight-Loss Drugs? Understanding GLP-1 Coverage in 2026 (condition-based coverage by drug; diagnosis determines coverage). wellcare.com
4. KFF — What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid (2025 policy decision; program context; Bridge extension). kff.org
5. Medicare.gov — How much does Medicare drug coverage cost? (2026 Part D out-of-pocket cap $2,100; maximum deductible $615). medicare.gov
6. Drugs.com — How much does Foundayo cost? (self-pay dose tiers from $149). drugs.com
7. NovoCare — GLP-1 Pharmacy / Wegovy self-pay pricing (~$349 ongoing; $199 intro for first two fills through June 30, 2026; Wegovy HD $399). novocare.com
8. Ro — Weight Loss Program Pricing (Ro Body membership; medication priced separately). ro.co
9. U.S. Food and Drug Administration — FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (April 30, 2026 proposal). fda.gov
10. U.S. Food and Drug Administration — FDA Approves First Treatment to Reduce Risk of Serious Heart Problems in Adults With Obesity or Overweight (Wegovy cardiovascular indication; GLP-1 boxed warning). fda.gov
11. KFF — BALANCE Model and Medicare GLP-1 Bridge (post-2027 uncertainty; voluntary plan participation). kff.org
12. NBC News — What to watch for in weight loss drugs in 2026 (Costco/Walmart cash pricing; LillyDirect and NovoCare launches; TrumpRx). nbcnews.com
13. Eli Lilly — Zepbound Self Pay Journey Program full terms & conditions ($299/$399/$449 prices; 45-day refill rule). lilly.com
14. U.S. News — Ro Weight Loss Review 2026 (Medicare cash-pay allowed; Medicaid not eligible; brand-name-only menu). health.usnews.com; also Ro’s own insurance page: ro.co
15. Sesame — Online weight loss program (Success by Sesame) (subscription $99/mo or as low as $59/mo annual; medication billed separately; menu). sesamecare.com
16. AJMC — Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices (TrumpRx navigator framework). ajmc.com
17. FDA / Eli Lilly — Foundayo (orforglipron) approval and indication; LillyDirect self-pay pricing. fda.gov; lilly.com
18. U.S. Food and Drug Administration — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (compounded GLP-1s not FDA-approved). fda.gov
19. U.S. Food and Drug Administration — Wegovy and Zepbound Prescribing Information (contraindications: MTC/MEN 2; warnings: pancreatitis, kidney injury, hypoglycemia, delayed gastric emptying). fda.gov
20. AARP — When Will the Cost of GLP-1 Weight Loss Drugs Go Down? (turning-65 cash-bridge guidance). aarp.org
21. Ro — 2025 GLP-1 Insurance Coverage Checker Report (free coverage checker used by hundreds of thousands of people). ro.co